Patents by Inventor Ned Sacktor

Ned Sacktor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of HIV-1-associated neurocognitive disorders
    Patent number: 10161925
    Abstract: Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: December 25, 2018
    Assignees: Temple University—Of The Commonwealth System of Higher Education, The Johns Hopkins University
    Inventors: Salim Merali, Carlos A. Barrerro, Kamel Khalili, Jay Rappaport, Norman J. Haughey, Ned Sacktor
  • Detection of HIV-1-Associated Neurocognitive Disorders
    Publication number: 20170176408
    Abstract: Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.
    Type: Application
    Filed: March 24, 2015
    Publication date: June 22, 2017
    Inventors: Salim Merali, Carlos A. Barrerro, Kamel Khalili, Jay Rappaport, Norman J. Haughey, Ned Sacktor